Price List - Idvynso - Antiretrovirals - Combinations.xlsx
XLSX spreadsheet 44 KB Posted
- Solicitation number
- HT9402-26-Q-9303
- Issued by
-
Defense Health Agency
About this file
This is a pricing template and quote submission form for antiretroviral combination pharmaceutical agents being considered for inclusion in the Department of War (DoW) Uniform Formulary (UF) during the August 5-6, 2026 P&T Committee meeting. The file contains blank appendices for ten newly approved drugs within the Antiretrovirals - Combinations subclass, with quotes due by June 29, 2026. Manufacturers must submit pricing for both Blanket Purchase Agreement (BPA) scenarios (Uniform Formulary and Non-Formulary designations) applicable to Military Treatment Facilities and Mail Order dispensing venues, along with Additional Discount Program (ADP) pricing for TRICARE Retail refunds at Tier 2 and Tier 3 formulary levels. Pricing must be provided on a per-unit basis (each, gram, mL, etc.) and remain consistent across all package sizes within a given dispensing venue.
The submission requires manufacturers to complete the Quote Review Checklist and provide fully executed signature pages alongside all quote information. Prior Authorization and Step Therapy provisions may apply to selected agents. Manufacturers must also submit responses to clinical questions via email to the designated RFQ Points of Contact. The pricing template uses the Federal Ceiling Price (FCP) methodology for non-FAMP discounts and Wholesale Acquisition Cost (WAC) for products without an FCP. This RFQ is part of solicitation HT9402-26-Q-9303 issued by the Defense Health Agency under 10 U.S.C. 1074g to establish pharmaceutical pricing agreements for the Military Health System.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Price List - Bysanti - Antipsychotic Agents - Atypical.xlsx | XLSX spreadsheet | |
| RFQ HT9402-26-Q-9303 NAD.pdf | ||
| Price List - Nereus - Antiemetic-Antivertigo Agents - NA.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf | ||
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price List - Zolymbus - Glaucoma Agents - Prostaglandin.xlsx | XLSX spreadsheet |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the August 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 |
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 174ARCOG1UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 174ARCOG1NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #2 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 174ARCOG1UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 174ARCOG1NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 174ARCOG1UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 174ARCOG1NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 174ARCOG1UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 174ARCOG1NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 174ARCOG1UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 174ARCOG1NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 174ARCOG1UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 174ARCOG1NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 174ARCOG1UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 174ARCOG1NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 174ARCOG1UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 174ARCOG1NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 174ARCOG1UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 174ARCOG1NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 174ARCOG1UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 174ARCOG1NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (non-FAMP Discount)
| UF ADP Appendix for the August 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 |
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 |
| Formulary Notes | |||
| Class Note(s): Class Note(s): Prior Authorization (PA) may apply. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote | ||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote | ||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (WAC Discount)
| UF ADP Appendix for the August 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 |
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DoW Uniform Formulary Class: | ANTIRETROVIRALS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | COMBINATIONS | Quotes due: | June 29, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 174ARCOG1T2NS1M | Tier 2 | 1 or more | |
| 174ARCOG1T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
File details come from the government source that posted it. Updated .